Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 260.5
(-1.14%)
TWD 260.5
(-1.14%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 11.58 Billion TWD | 29.9% |
| 2022 | 8.91 Billion TWD | 39.61% |
| 2021 | 6.38 Billion TWD | 16.68% |
| 2020 | 5.47 Billion TWD | 10.99% |
| 2019 | 4.93 Billion TWD | 138.11% |
| 2018 | 2.07 Billion TWD | -60.86% |
| 2017 | 5.29 Billion TWD | 7.46% |
| 2016 | 4.92 Billion TWD | 8.15% |
| 2015 | 4.55 Billion TWD | 8.38% |
| 2014 | 4.2 Billion TWD | 1042.91% |
| 2013 | 367.63 Million TWD | 196.95% |
| 2012 | 123.8 Million TWD | 1166.02% |
| 2011 | 9.77 Million TWD | -96.94% |
| 2010 | 319.86 Million TWD | 454.94% |
| 2009 | 57.63 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 10.66 Billion TWD | -8.35% |
| 2024 Q1 | 11.63 Billion TWD | 0.47% |
| 2023 Q2 | 11.08 Billion TWD | 2.89% |
| 2023 FY | 11.58 Billion TWD | 29.9% |
| 2023 Q1 | 10.77 Billion TWD | 20.85% |
| 2023 Q3 | 11.78 Billion TWD | 6.26% |
| 2023 Q4 | 11.58 Billion TWD | -1.68% |
| 2022 Q4 | 8.91 Billion TWD | 13.58% |
| 2022 Q3 | 7.85 Billion TWD | 12.27% |
| 2022 Q2 | 6.99 Billion TWD | -3.59% |
| 2022 FY | 8.91 Billion TWD | 39.61% |
| 2022 Q1 | 7.25 Billion TWD | 13.55% |
| 2021 Q3 | 6.29 Billion TWD | -10.74% |
| 2021 Q1 | 6.92 Billion TWD | 26.48% |
| 2021 FY | 6.38 Billion TWD | 16.68% |
| 2021 Q2 | 7.05 Billion TWD | 1.87% |
| 2021 Q4 | 6.38 Billion TWD | 1.46% |
| 2020 Q2 | 5.69 Billion TWD | 6.22% |
| 2020 Q1 | 5.35 Billion TWD | 8.6% |
| 2020 FY | 5.47 Billion TWD | 10.99% |
| 2020 Q4 | 5.47 Billion TWD | -1.09% |
| 2020 Q3 | 5.53 Billion TWD | -2.73% |
| 2019 FY | 4.93 Billion TWD | 138.11% |
| 2019 Q4 | 4.93 Billion TWD | 1.34% |
| 2019 Q3 | 4.86 Billion TWD | 29.67% |
| 2019 Q1 | 3.79 Billion TWD | 83.23% |
| 2019 Q2 | 3.75 Billion TWD | -1.11% |
| 2018 Q2 | 3.27 Billion TWD | -32.93% |
| 2018 Q3 | 3.09 Billion TWD | -5.31% |
| 2018 FY | 2.07 Billion TWD | -60.86% |
| 2018 Q1 | 4.87 Billion TWD | -7.86% |
| 2018 Q4 | 2.07 Billion TWD | -33.11% |
| 2017 Q3 | 4.65 Billion TWD | 0.6% |
| 2017 Q4 | 5.29 Billion TWD | 13.62% |
| 2017 FY | 5.29 Billion TWD | 7.46% |
| 2017 Q1 | 4.72 Billion TWD | -4.06% |
| 2017 Q2 | 4.63 Billion TWD | -2.0% |
| 2016 Q4 | 4.92 Billion TWD | 6.04% |
| 2016 FY | 4.92 Billion TWD | 8.15% |
| 2016 Q3 | 4.64 Billion TWD | 1.69% |
| 2016 Q2 | 4.56 Billion TWD | -0.25% |
| 2016 Q1 | 4.57 Billion TWD | 0.55% |
| 2015 Q1 | 4.21 Billion TWD | 0.38% |
| 2015 Q2 | 4.21 Billion TWD | 0.05% |
| 2015 Q3 | 4.69 Billion TWD | 11.15% |
| 2015 Q4 | 4.55 Billion TWD | -2.91% |
| 2015 FY | 4.55 Billion TWD | 8.38% |
| 2014 Q1 | 373.85 Million TWD | 1.69% |
| 2014 Q3 | 462.02 Million TWD | 24.35% |
| 2014 Q2 | 371.55 Million TWD | -0.62% |
| 2014 FY | 4.2 Billion TWD | 1042.91% |
| 2014 Q4 | 4.2 Billion TWD | 809.43% |
| 2013 Q2 | 181.78 Million TWD | 13.9% |
| 2013 Q3 | 324.36 Million TWD | 78.43% |
| 2013 Q4 | 367.63 Million TWD | 13.34% |
| 2013 FY | 367.63 Million TWD | 196.95% |
| 2013 Q1 | 159.59 Million TWD | 28.91% |
| 2012 FY | 123.8 Million TWD | 1166.02% |
| 2012 Q1 | 277.84 Million TWD | 2741.25% |
| 2012 Q2 | 354.64 Million TWD | 27.64% |
| 2012 Q3 | 377.68 Million TWD | 6.5% |
| 2012 Q4 | 123.8 Million TWD | -67.22% |
| 2011 Q2 | 334.12 Million TWD | 1.66% |
| 2011 Q1 | 328.66 Million TWD | 2.75% |
| 2011 FY | 9.77 Million TWD | -96.94% |
| 2011 Q4 | 9.77 Million TWD | -96.96% |
| 2011 Q3 | 321.67 Million TWD | -3.73% |
| 2010 Q4 | 319.86 Million TWD | 0.0% |
| 2010 FY | 319.86 Million TWD | 454.94% |
| 2009 FY | 57.63 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | -5904.97% |
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | -970.683% |
| Maywufa Company Ltd. | 442.66 Million TWD | -2517.05% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | -1765.196% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -439383.649% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | -834.691% |
| PhytoHealth Corporation | 28.11 Million TWD | -41105.012% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | -1011.278% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | -185.03% |
| PharmaEssentia Corporation | 1.2 Billion TWD | -865.221% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | -131.24% |